-
公开(公告)号：US20230365627A1
公开(公告)日：2023-11-16
申请号：US18029847
申请日：2021-10-01
Applicant: Bristol-Myers Squibb Company
Inventor： Tao WANG
Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
-
公开(公告)号：US20230063238A1
公开(公告)日：2023-03-02
申请号：US17791023
申请日：2020-11-19
Applicant: Bristol-Myers Squibb Company
Inventor： Tao WANG , Paul Michael SCOLA , Zhongxing ZHANG
IPC: C07D513/14 , A61P35/00
Abstract: In accordance with the present disclosure, macrocyclic compounds of formula (I) have been discovered that bind to PD-L1 and are capable of inhibiting the interaction of PD-L1 with PD-1 and CD80. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.
-
公开(公告)号：US20230022400A1
公开(公告)日：2023-01-26
申请号：US17777917
申请日：2020-11-19
Applicant: Bristol-Myers Squibb Company
Inventor： Tao WANG , Paul Michael SCOLA , Zhongxing ZHANG
IPC: C07K7/56
Abstract: In accordance with the present disclosure, macrocyclic compounds have been discovered that bind to PD-L1 and are capable of inhibiting the interaction of PD-L1 with PD-1 and CD80. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.
-
4.发明申请公开(公告)号：US20170101416A1
公开(公告)日：2017-04-13
申请号：US15312022
申请日：2015-05-19
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Tao WANG , Zhongxing Zhang , John F. Kadow
IPC: C07D491/048 , C07D405/10
CPC classification number: C07D491/048 , C07D307/84 , C07D405/10
Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV: formula (I).
-
公开(公告)号：US20160024111A1
公开(公告)日：2016-01-28
申请号：US14771827
申请日：2014-03-05
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Tao WANG , Zhiwei YIN , Paul Michael SCOLA
IPC: C07D498/08 , A61K45/06 , A61K31/53
CPC classification number: C07D498/08 , A61K31/53 , A61K45/06
Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
-
Patent Agency Ranking
公开(公告)号：US20150368267A1
公开(公告)日：2015-12-24
申请号：US14765910
申请日：2014-02-04
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Tao WANG , Zhongxing ZHANG , Zhiwei YIN , Li-Qiang SUN , Eric MULL , Qian ZHAO , Paul Michael SCOLA
IPC: C07D498/22 , A61K31/53 , C07D498/20 , A61K31/551 , C07D498/08 , A61K45/06 , C07D498/18
CPC classification number: C07D498/22 , A61K31/53 , A61K31/551 , A61K45/06 , C07D498/08 , C07D498/18 , C07D498/20
Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
Abstract translation: 除了使用这些化合物的组合物和方法之外，还列举了式I化合物，包括其药学上可接受的盐。 该化合物具有抗丙型肝炎病毒（HCV）的活性，可用于治疗HCV感染者。
-
公开(公告)号：US20230065827A1
公开(公告)日：2023-03-02
申请号：US17791027
申请日：2020-11-19
Applicant: Bristol-Myers Squibb Company
Inventor： Tao WANG , Paul Michael SCOLA , Zhongxing ZHANG
Abstract: In accordance with the present disclosure, macrocyclic compounds have been discovered that bind to PD-L1 and are capable of inhibiting the interaction of PD-L1 with PD-1 and CD80. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.
-
公开(公告)号：US20230365628A1
公开(公告)日：2023-11-16
申请号：US18030604
申请日：2021-10-08
Applicant: Bristol-Myers Squibb Company
Inventor： Tao WANG
Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
-
公开(公告)号：US20170121340A1
公开(公告)日：2017-05-04
申请号：US15317541
申请日：2015-06-10
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Tao WANG , Zhongxing Zhang , Kyle E. Parcella , Kyle J. Eastman , John F. Kadow
IPC: C07D491/048 , C07D307/84
CPC classification number: C07D491/048 , C07D307/84 , C07D405/12 , C07D491/04
Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV:
-
公开(公告)号：US20150368251A1
公开(公告)日：2015-12-24
申请号：US14765906
申请日：2014-02-04
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Tao WANG , Zhongxing ZHANG , Eric GILLIS , Paul Michael SCOLA
IPC: C07D487/08 , A61K31/53
CPC classification number: C07D487/08 , A61K31/53 , C07D498/08
Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
Abstract translation: 除了使用这些化合物的组合物和方法之外，还列举了式I化合物，包括其药学上可接受的盐。 该化合物具有抗丙型肝炎病毒（HCV）的活性，可用于治疗HCV感染者。
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.023 seconds)
